Status:

TERMINATED

Treatment of Radiation Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)

Lead Sponsor:

Manhattan Eye, Ear & Throat Hospital

Collaborating Sponsors:

Alcon Research

Conditions:

Eye Injuries

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Radiation retinopathy is a disease of the retina. It occurs in people who have received or been exposed to radiation near the eyes. The blood vessels are abnormal and may grow which lead to scarring a...

Detailed Description

Patients will receive an injection of 15 mg of Anecortave acetate behind the eye to be treated ("study eye"). They will be evaluated every six months to determine if their condition is stable or worse...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of radiation retinopathy.
  • Patients must be 18 years of age or older to receive treatment.
  • Visual acuity of 20/30 to 20/320 in study eye on the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity chart
  • Visual acuity of 20/800 or better in fellow eye on the ETDRS visual acuity chart.

Exclusion

  • Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.
  • Patients who have undergone intraocular surgery within the last 2 months
  • Patient participating in any other investigational drug study.
  • Use of an investigational drug or treatment related or unrelated to their condition within 30 days prior to receipt of study medication.
  • Inability to obtain photographs to document choroidal neovascularization (CNV) (including difficulty with venous access)
  • Patient with significant liver disease or uremia.
  • Patient with known adverse reaction to fluorescein and indocyanine green or iodine.
  • Patient has a history of any medical condition which would preclude scheduled visits or completion of study
  • Patient has had insertion of scleral buckle in the study eye
  • Patient has received radiation treatment
  • Patient is on anticoagulant therapy with the exception of aspirin
  • Patient is pregnant or nursing.

Key Trial Info

Start Date :

April 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2007

Estimated Enrollment :

2 Patients enrolled

Trial Details

Trial ID

NCT00211367

Start Date

April 1 2004

End Date

March 1 2007

Last Update

June 21 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Manhattan Eye, Ear & Throat Hospital

New York, New York, United States, 10021